Attention FDA: All Medical Technologies Are Not Alike
COMMENTARY

July 19, 2022by Peter Pitts, Visiting Professor, University of Paris School of Medicine
Attention FDA: All Medical Technologies Are Not Alike

What exactly is a “medical technology?” It depends who you ask, but the general definition is it’s a tool that addresses a health care need. But, just as all health care needs are not the same (allergies are one, cancer another), neither are medical technologies.

This is pretty much common sense, so it’s surprising that the Food & Drug Administration has opted to lump all medical devices into one regulatory basket when it comes to managing supply chain and shortage issues.

The FDA has issued guidance — Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the Food, Drug & Cosmetic Act — and recently held a multi-day public stakeholder meeting to give medical device manufacturers assistance in complying with laws requiring manufacturers to notify the agency of a permanent discontinuance or disruption in the manufacture of a device during or in advance of a public health emergency. That’s good.

The problem is that the FDA fails to acknowledge something very basic — all medical devices are not the same. There’s no recognition, for example, between multi-use devices, such as imaging systems, and single-use medical devices, defined by the FDA as a disposable device intended for use on one patient during a single procedure. The result is that the agency will mandate the collection of vast amounts of information it doesn’t need to avoid or ameliorate a product shortage during a public health emergency.

It would be a costly mistake for the FDA to apply a one-size-fits-all approach to medical device supply chain challenges in all health care technologies without recognizing the need for more specific requirements based on the actual technology, be they multi-use devices, single use devices or drugs. Such an unsophisticated approach fails to address the root causes behind real health care technology shortages. In short, rather than fix the problem, it creates more costs and complications.

The good news is that manufacturers have extensive resources dedicated to supply chain management and have every incentive to forecast and mitigate supply chain challenges.

To address these concerns, the FDA guidance should be more precise in scope to quantitatively help prevent or mitigate shortages during or in advance of a public health emergency, specifically:

  • The agency shouldn’t require reports on devices that are not relevant to supply chain shortages. Such overbroad regulatory language will needlessly burden manufacturers and lead to irrelevant information overloading an already under-resourced FDA.
  • Discussions regarding supply chain challenges shouldn’t conflate medical devices and pharmaceuticals. They are different technologies and must be addressed differently. For example, medical devices often contain hundreds or thousands of parts and components, significantly more than even the most advanced pharmaceuticals.
  • The FDA’s guidance must account for differences between consumable and multi-use or capital equipment, such as a CT, MRI, linear accelerator or colonoscope.
  • The FDA should recognize distinctions with a difference between capital equipment, such as imaging equipment, drugs or single-use devices.
  • There are often multiple device vendors that have several versions or models of the same device types in use, whereas pharmaceuticals tend to have few if any alternatives. If one device manufacturer experiences an interruption in production, there are usually numerous options to fulfill market demand.
  • Hospitals have an installed base of “redundant” imaging equipment — similar systems installed from multiple manufacturers for use — often for multiple years.
  • Capital medical equipment is often built to order, not built to stock, as is typical with drugs and single-use devices.
  • A significant portion of the new market for capital equipment is replacing devices already in use, meaning health care facilities continue to use the products they already own for patient care in the event of an unexpected delay in receiving new systems.

The current guidance, as written, could overburden manufacturers, leading to expensive and irrelevant paperwork being submitted to the agency, wasting valuable agency capacity and resources that are not helpful in addressing issues relevant to product shortages. The agency should also consider what kinds of regulatory flexibilities it can implement during public health emergencies that will enable manufacturers to better manage their suppliers and mitigate shortages.

Simply put, medical imaging and multi-use technologies are unique, and the FDA should account for these differences in health care technologies in its shortage reporting requirements. More information isn’t always better. Communicating the right information about the right devices at the right time between manufacturers and the FDA is the key to success.


Peter J. Pitts, a former FDA associate commissioner and member of the United States Senior Executive Service, is president of the Center for Medicine in the Public Interest and a visiting professor at the University of Paris School of Medicine. You can reach him on LinkedIn.

A+
a-

In The News

Health

Voting

Opinions

New Poll Results Show Americans Are Concerned About Political Division and What Can Be Done to Fix It

As we head into this election year with a likely rematch between two relatively unpopular candidates, it may seem political divisions... Read More

As we head into this election year with a likely rematch between two relatively unpopular candidates, it may seem political divisions are higher than ever. Many controversial issues like immigration, taxes and debate over foreign aid dominate the news, so much so that many Americans may think... Read More

Ensuring Equity and Innovation in Kidney Care: a Call to Action During National Kidney Month

When you woke up this morning, you probably turned on the light, maybe looked at your phone or went to... Read More

When you woke up this morning, you probably turned on the light, maybe looked at your phone or went to get a glass of water, all without much thought. Electricity, phone service and running water are all essentials that we give little thought to until they’re... Read More

The American Rescue Plan Is (Still) Worth Celebrating

Just three years ago, our economy was in the midst of an unprecedented crisis. Communities across the nation were reeling... Read More

Just three years ago, our economy was in the midst of an unprecedented crisis. Communities across the nation were reeling not only from the health implications of the COVID pandemic, but also from high unemployment, business closures and frightening economic uncertainty. Bold and decisive action was... Read More

Cutting Through the Generative AI Noise: What Business Leaders Should Do Now

No matter what industry you’re in, there are two things that every business leader cares about: revenue growth and cost reduction. These are the... Read More

No matter what industry you’re in, there are two things that every business leader cares about: revenue growth and cost reduction. These are the metrics that CEOs talk about ad nauseam during earnings calls. They are the keys that unlock higher business valuations, individual performance bonuses and the ever elusive... Read More

Shield Our Eyes: Lawmakers Across the Country Must Ensure Eye Surgery Can Only Be Performed by Medical Eye Surgeons 

Training and experience matter, especially when health is on the line. Just as one would rightly be concerned to discover... Read More

Training and experience matter, especially when health is on the line. Just as one would rightly be concerned to discover a flight attendant, rather than a pilot, flying their airplane, so too would most people be alarmed to find the person performing surgery on and around... Read More

Fentanyl Kills More Than 150 Americans Each Day, but Some States Keep Overdose Rescue Medications Out of Reach 

Today’s growing overdose epidemic is being fueled by fentanyl, a synthetic opioid that is 50 times stronger than heroin and 100... Read More

Today’s growing overdose epidemic is being fueled by fentanyl, a synthetic opioid that is 50 times stronger than heroin and 100 times stronger than morphine. In fact, it’s so lethal that only a tiny amount — 2 milligrams, about the size of a pencil tip — can... Read More

News From The Well
scroll top